Takeda Reports 3.7% Year-over-Year Revenue Growth at Constant Exchange Rates in Q1 FY2023

On August 7, Takeda Pharmaceutical Company Limited announced its first-quarter performance for the fiscal year 2023 ended June 30. Revenue for the first quarter reached 1,058.6 billion yen, representing an 8.9% year-over-year increase at actual exchange rates and a 3.7% growth at constant exchange rates, with a core operating profit margin of 30.8%.